The Clinical Trials Office (CTO) provides administrative, research and educational services to the Cancer Institute investigators and research staff conducting clinical trials. It serves as the main coordinating center for cancer-related clinical trials from concept development and submission to closure including protocol development, regulatory and compliance guidance, administrative submissions, data collection and data management, data analysis, and quality control functions, and serves as the administrative interface to other clinical research organizations at the NYU Medical Center. The goals of this resource are to: Facilitate clinical trials by providing a framework for development, submission, and conduct of clinical trials. Enhance and facilitate data collection and reporting of clinical cancer research data. Provide educational programs for the CTO staff and clinical investigators. Promote interdisciplinary collaboration and a venue for translating research findings to the clinical arena In response to the previous critique, internal audits, and the review of external consultants, significant changes have occurred within the CTO since the last review. These changes include the appointment of new medical and administrative directors, new standard operating procedures, and restructuring of data management. These improvements have produced a CTO that better meets the needs of investigators performs more effectively within the NYU School of Medicine clinical research environment. Currently, the CTO supervises 49 research staff and manages 158 open protocols. The CTO continues to expand and improve its function to serve as the central coordinating center for the clinical research enterprise at the NYUCI.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016087-30
Application #
8038255
Study Section
Subcommittee G - Education (NCI)
Project Start
2010-03-01
Project End
2013-02-28
Budget Start
2010-03-01
Budget End
2011-02-28
Support Year
30
Fiscal Year
2010
Total Cost
$174,324
Indirect Cost
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Fan, Xiaozhou; Peters, Brandilyn A; Jacobs, Eric J et al. (2018) Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults. Microbiome 6:59
Chen, Danqi; Fang, Lei; Mei, Shenglin et al. (2018) Erratum: ""Regulation of Chromatin Assembly and Cell Transformation by Formaldehyde Exposure in Human Cells"". Environ Health Perspect 126:019001
Khodadadi-Jamayran, Alireza; Akgol-Oksuz, Betul; Afanasyeva, Yelena et al. (2018) Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process. Oncotarget 9:12868-12878
Wadghiri, Youssef Z; Hoang, Dung Minh; Leporati, Anita et al. (2018) High-resolution Imaging of Myeloperoxidase Activity Sensors in Human Cerebrovascular Disease. Sci Rep 8:7687
Wang, Shiyang; Liechty, Benjamin; Patel, Seema et al. (2018) Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J Neurooncol 138:183-190
Nancy, Patrice; Siewiera, Johan; Rizzuto, Gabrielle et al. (2018) H3K27me3 dynamics dictate evolving uterine states in pregnancy and parturition. J Clin Invest 128:233-247
Schulfer, Anjelique F; Battaglia, Thomas; Alvarez, Yelina et al. (2018) Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice. Nat Microbiol 3:234-242
Ge, Wenzhen; Clendenen, Tess V; Afanasyeva, Yelena et al. (2018) Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts. Int J Cancer 142:2215-2226
Ruggles, Kelly V; Wang, Jincheng; Volkova, Angelina et al. (2018) Changes in the Gut Microbiota of Urban Subjects during an Immersion in the Traditional Diet and Lifestyle of a Rainforest Village. mSphere 3:
Winer, Benjamin Y; Shirvani-Dastgerdi, Elham; Bram, Yaron et al. (2018) Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Sci Transl Med 10:

Showing the most recent 10 out of 1170 publications